What Benadryl Is Actually Doing to an Older Brain

The dementia headline is the weakest part of the case against this drug. The falls, the delirium and the next-day impairment are the strong part, and almost nobody makes that case.

What is Benadryl, and why is it different from other allergy medicines?

Diphenhydramine, the active ingredient in Benadryl, is a first-generation antihistamine that crosses into the brain and blocks acetylcholine — unlike newer allergy drugs designed to stay out of it.

Antihistamines treat allergies by blocking histamine, but first-generation antihistamines like diphenhydramine also cross the blood-brain barrier and block a second chemical messenger: acetylcholine. Acetylcholine is essential for memory, attention, and muscle control, which is exactly why blocking it makes you drowsy — and exactly why researchers have started asking what it does over years of regular use.

This isn't a niche ingredient. Diphenhydramine (and its close cousin doxylamine, found in original Unisom SleepTabs) is the active sleep ingredient in far more products than most families realize: Tylenol PM, Advil PM, Aleve PM, ZzzQuil, and most store-brand "nighttime" cold and pain formulas. A caregiver managing a loved one's medications can easily miss that a nightly "PM" pill and a daytime allergy pill are quietly stacking the same anticholinergic load.

What does the research actually show?

Less than this page originally said. The dose-dependent link is real for strong anticholinergics as a group — but the two largest studies to look at antihistamines on their own found no dementia signal for them.

Corrected August 2026. An earlier version of this page presented the 54% figure as though it described diphenhydramine. It does not, and the correction is worth leading with.

The best-known study, led by Shelly Gray and colleagues and published in JAMA Internal Medicine in 2015, followed 3,434 older adults for an average of seven years. People with the highest cumulative anticholinergic use had an adjusted hazard ratio of 1.54 for dementia — the 54% — and the risk rose with total dose over time.

What rarely travels with that number is what the exposure was made of. Gray's own Table 2 breaks it down: antihistamines were the most widely used class, taken by 64.8% of participants, but accounted for just 17.2% of the total standardized daily doses. Antidepressants, used by fewer people at higher cumulative doses, accounted for 63.1%. No antihistamine-specific hazard ratio was ever published. In fairness, Gray's team did test the objection — a sensitivity analysis splitting antidepressants from all other classes found risk elevated in both — so that paper is not silent on the question.

What came next is what settles it, and it points the other way. Coupland and colleagues (JAMA Internal Medicine, 2019) compared 58,769 people with dementia against 225,574 controls and wrote that there were “no significant increases in risk associated with antihistamines” — while finding clear associations for antidepressants, bladder antimuscarinics, antiparkinson and antiepileptic drugs in the same analysis. Richardson and colleagues (BMJ, 2018), in a separate UK database of 40,770 cases and 283,933 controls, found antihistamines null at every time window they examined, including 15 to 20 years before diagnosis.

The proposed mechanism lines up with what's already known about Alzheimer's disease: the condition itself involves a loss of cholinergic neurons and falling acetylcholine levels, which is why the standard Alzheimer's medications (donepezil, rivastigmine, galantamine) work by boosting acetylcholine. Taking a drug that blocks the very chemical those medications are trying to raise is, at minimum, working against the body's own aging brain chemistry.

All of these are observational studies. None can prove causation in either direction, and people who need frequent sleep aids or allergy medication differ from those who don't in ways researchers cannot fully account for — including, importantly, that poor sleep and depression are themselves early signs of dementia. That last point cuts against the alarming reading, not for it.

How much use is “risky”?

For the risks that are established — falls, delirium, next-day impairment — the threshold is lower than people think. For dementia, there is no established threshold for antihistamines at all.

Gray's heaviest-exposure category was more than three years of daily use of a strong anticholinergic — but that was measured across all classes, using a standardized dose unit, not in milligrams of diphenhydramine. Converting it into “50mg of Benadryl for three years” is an extrapolation the paper does not make, and an earlier version of this page made it.

The falls evidence needs no such extrapolation. A 2018 systematic review and meta-analysis in Osteoporosis International pooled five observational studies in older adults and found first-generation antihistamine use associated with an odds ratio of 2.03 for injurious falls or fracture, with zero heterogeneity between studies. Roughly doubled odds of the fall that ends in an emergency room. And a randomized crossover trial in Annals of Internal Medicine put licensed drivers through a driving simulator after diphenhydramine 50mg and after alcohol: driving was worse after the diphenhydramine. Self-reported drowsiness barely correlated with actual impairment.

The instinct after reading a headline like the old version of this one is panic and abrupt discontinuation. That was never the goal. The goal is noticing a pattern of long-term daily use and bringing it to a doctor — and the reason to bring it is the fall risk and the daytime fog, which are solid, rather than a dementia number that was never about this drug.

The full evidence review is here — what each study measured, and why the number keeps getting misquoted.

What should caregivers do?

If a loved one reaches for Benadryl, a “PM” product, or Unisom most nights, it's worth a conversation with their doctor about safer long-term alternatives.

• Check labels for “diphenhydramine” or “doxylamine” hiding in sleep aids, PM pain relievers, and nighttime cold medicines — the brand name often doesn't mention the ingredient.
• Ask the doctor or pharmacist about non-anticholinergic alternatives for sleep or allergies, such as melatonin, low-dose trazodone, or second-generation antihistamines like loratadine or cetirizine.
• Don't stop a long-term medication cold turkey — work with a doctor or pharmacist on a taper plan, especially for sleep, since abrupt withdrawal can cause rebound insomnia.
• Bring every medication and OTC product to the next appointment (a “brown-bag review”) so the doctor can see the full picture, not just the prescriptions.